Flecainide in Treating Patients With Chronic Neuropathic Pain
CompletedPhase 2NCT00002996
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS.
Study details
- Official title
- Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial
- Conditions
- Interventions
- Drug: flecainide acetate
- Sponsor
- Eastern Cooperative Oncology Group
- Collaborators
- National Cancer Institute (NCI)
- Start date
- 1998-05-04
- Primary completion
- 2006-04
- Sex
- All
- Age range
- from 19 Years to 120 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 6
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
DISEASE CHARACTERISTICS: * Chronic neuropathic pain with diagnosis of cancer or AIDS PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * SGOT no greater than 2 times upper limit of normal (ULN) Renal: * Creatinine no greater than 2 times ULN Cardiovascular: * No clinical history of infarction or angina * No advanced heart failure * No sick sinus syndrome, intraventricular conduction disease, second or third degree AV block or arrhythmias requiring treatment (exception may be granted by cardiac consult) * No focal wall motion abnormalities * Ejection fraction at least 40% * Systolic blood pressure at least 90 mm Hg Other: * Must be able to take oral medication * No known allergy or adverse reaction to flecainide, mexilitene or any other type I antiarrhythmic drug * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 2 weeks since prior chemotherapy that may cause neuropathy Endocrine therapy: * At least 2 weeks since prior corticosteroids Radiotherapy: * Not specified Surgery: * Not specified Other: * No tricyclic antidepressant treatment within past 2 weeks * No concurrent use of flecainide, mexiletene or any other type I antiarrhythmic drug
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00002996